Skip to main content
OpenTrials
Completed

NCT Number: NCT03141125

The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy

Study about the effect of ethanol extract physalis angulate in scleroderma patients with standard therapy to reduce skin fibrosis based on modified Rodnan Skin Score, reduce inflammation, immunological response and fibrosis: A Randomized Clinical Placebo ControlledTrial with a prospective cohort study on scleroderma outpatient clinic in Cipto Mangunkusumo Hospital in Jakarta and Hasan Sadikin Hospital in Bandung, from January 2016 to July 2017

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hasan Sadikin Hospital, Bandung, West Java, Indonesia

Loading trial locations.

About this study

Background.

Scleroderma is a systemic autoimmune disease that can not be cured, the progression of the disease still difficult to prevent and lead to increased morbidity and mortality. Disease-modifying anti-rheumatic drugs (DMARDs) as standard immunosuppressant drugs to reduce, eliminate, inhibit inflammation and fibrosis in scleroderma patient is still less effective.

Objectives.

To evaluate the effect of ethanol extract of Physalis angulate Linn to reduce skin fibrosis based on MRSS, ESR, BAFF, sCD40L, and P1NP in scleroderma patients with standard therapy

Methods.

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on scleroderma patients with standard therapy, who admitted to Cipto Mangunkusumo Hospital Jakarta and Hasan Sadikin Hospital Bandung, from January 2016 to July 2017.

Patients must be controlled every month until three months for follow up. Subjects were divided into two parallel group, one of intervention group, and one of placebo group

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who meet the criteria of the type of limited scleroderma diagnosis / limited or diffuse type.
  • Patients who routine control in rheumatology outpatient clinics in Ciptomangunkusumo hospital Jakarta and Hasan Sadikin hospital Bandung RSHS who received standard therapy for scleroderma with a stable dose over the past 3 months.
  • The research subjects aged 15 to 60 years.
  • Subjects with modified Rodnan Skin score ≥ 5.
  • Disease duration ≥ 1 year

Exclusion criteria

  • Impaired liver function with cirrhosis
  • Chronic Renal dysfunction (chronic kidney disease stages 4-5). Or creatinine levels> 2 mg / dL in the last 1 month prior to randomization.
  • Other autoimmune disease/overlap syndrome.
  • Received a steroid/prednisone >10 mg/day in the last 1 month.
  • Patients who are pregnant or breastfeeding.
  • Patients with active tuberculosis and or are being treated with anti-tuberculosis medicines.
  • Severe heart disease. (Heart Disease with impaired function according to the New York Heart Association Class III or IV)
  • History of allergies to herbal Ciplukan / Physalis angulate Linn. or a history of hypersensitivity to certain drugs.
  • Hypotension (BP <90/60 mmHg)
  • Hypoglycemia (Glucose level <70 mg / dL)
  • Do not want to participate in the study

Treatment and study plan

Physalis angulata ethanol extract

Other

Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months

Other names: Herba Ciplukan, Ethanol extract of Physalis angulata Linn, Ethanol extract of Physalis angulata

Placebo

Other

No active component at the same dosage of 3x250 mg/day given orally for 3 months

Other names: Amylum

Primary outcomes

  1. Degree of skin fibrosis based on modified Rodnan Skin Score (mRSS)

    Time frame: 3 months of intervention

    Clinical improvement of skin fibrosis in scleroderma patients measured by modified Improvement in skin fibrosis is defined if there is a significant reduced of mRSS.

Secondary outcomes

  1. Level of P1NP serum

    Time frame: 3 months of intervention

    Improvement is defined if there is a significant reduced of P1NP serum level

  2. Value of ESR

    Time frame: 3 months of intervention

    Improvement is defined if there is a significant reduced of ESR value

  3. Level of BAFF serum

    Time frame: 3 months of intervention

    Improvement is defined if there is a significant reduced of BAFF serum level

  4. Level of sCD40L serum

    Time frame: 3 months of intervention

    Improvement is defined if there is a significant reduced of sCD40L serum level.

Sponsors and collaborators

Lead sponsor

Indonesia University

Other

Collaborators

  • Netherlands: Ministry of Health, Welfare and Sports

Registry information

Official study title

The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy to Reduce Skin Fibrosis Based on Modified Rodnan Skin Score, Reduce Inflammation, Immunological Response and Fibrosis

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
May 4, 2017
Registry last updated
Aug 29, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.